Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Gynecological Cancer × anlotinib × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 5 Sarcoma 2 Neoplasm Metastasis 2 Endometrial Neoplasms 2 Uterine Cervical Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma, Ewing 1 Ovarian Neoplasms 1 Neoplasms 1 Nasopharyngeal Carcinoma 1 Gynecological Cancer 1 Glioblastoma 1 Craniopharyngioma 1 Carcinoma, Hepatocellular 1 Anlotinib 1 Adenocarcinoma of Lung 1

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04236362 2021-01-12

A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Unknown

Gynecological Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡